ErbB Receptors

"ErbB Receptors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A family of structurally-related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS.

Descriptor ID	D066246
MeSH Number(s)	D08.811.913.696.620.682.725.400.009 D12.776.543.750.630.009 D12.776.543.750.750.400.074
Concept/Terms	ErbB Receptors ErbB Receptors Receptors, ErbB Receptors, Epidermal Growth Factor-Urogastrone Receptors, Epidermal Growth Factor Urogastrone Receptors, Epidermal Growth Factor EGF Receptors Receptors, EGF Epidermal Growth Factor Receptor Family Proteins HER Family Receptors Family Receptors, HER Receptors, HER Family Erb-b2 Receptor Tyrosine Kinases Erb b2 Receptor Tyrosine Kinases

Below are MeSH descriptors whose meaning is more general than "ErbB Receptors".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
ErbB Receptors [D08.811.913.696.620.682.725.400.009]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
ErbB Receptors [D12.776.543.750.630.009]
Receptors, Peptide [D12.776.543.750.750]
Receptors, Growth Factor [D12.776.543.750.750.400]
ErbB Receptors [D12.776.543.750.750.400.074]

Below are MeSH descriptors whose meaning is related to "ErbB Receptors".

Below are MeSH descriptors whose meaning is more specific than "ErbB Receptors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "ErbB Receptors" by people in this website by year, and whether "ErbB Receptors" was a major or minor topic of these publications.

Bar chart showing 102 publications over 28 distinct years, with a maximum of 10 publications in 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
1999	1	2	3
2001	1	0	1
2002	0	2	2
2003	2	0	2
2004	2	0	2
2005	0	3	3
2006	0	2	2
2007	4	2	6
2008	2	2	4
2009	2	0	2
2010	2	3	5
2011	2	2	4
2012	8	2	10
2013	5	3	8
2014	4	5	9
2015	1	1	2
2016	1	4	5
2017	0	2	2
2018	2	3	5
2019	0	3	3
2020	0	3	3
2021	1	2	3
2022	0	3	3
2023	0	1	1
2024	3	0	3
2025	1	3	4
2026	3	1	4

Below are the most recent publications written about "ErbB Receptors" by people in Profiles.

Moiseenko F, Stroyakovskiy D, Levchenko E, Fedyanin M, Gabina A, Oganesian A, Belukhin S, Stepanova M, Stepanova E, Artemyeva E, Myslik A, Volkov N, Bogdanov A, Shuginova T, Kryukov K, Kheinshtein V, Allakhverdiev A, Zaberegniy I, Akhmadiyarova Y, Popov M, Danilova A, Sehniaidze D, Savelov N, Levchenko N, Slugin E, Lopushanskaya O, Kuligina E, Aleksakhina S, Iyevleva A, Ivantsov A, Moiseyenko V, Imyanitov E. Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR-Mutated Locally Advanced or Metastatic Lung Cancer. Int J Cancer. 2026 Nov 01; 159(9):2244-2261.

View in: PubMed
Weiss GJ, Loftus JC, Mallery DW, Tran NL. Structure-guided identification and biological evaluation of reversible EGFR C797S inhibitors. Sci Rep. 2026 May 04; 16(1).

View in: PubMed
Porto SA, Birdsall GA, Harper NW, Honeywell ME, Leighow SM, Naylor TE, Ward KM, Wesley MK, Pritchard JR, Lee MJ. Genome-wide profiling identifies the genetic dependencies of cell death following EGFR inhibition. J Biol Chem. 2026 May; 302(5):111414.

View in: PubMed
Han F, Lv X, Zhou YJ, He Q, Guo Y, Xiang YQ, Shu XL, Pan SM, Qu SH, Zhang P, Jiang Y, Xu MJ, Lei KJ, Qu S, Wang XH, Jin YS, Zhao B, Dai R, Wang FH, Xu RH. Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial. Med. 2026 Apr 10; 7(4):101029.

View in: PubMed
Shin JH, Kim JY, Kim SH, Kang Y, Lee HJ, Kim MJ, Choi J, Jeong SK, Park SO, Cho YB, Kim KK, Shim JH, Chun E, Lee KY. USP11 promotes colorectal cancer progression by stabilizing EGFR and TRAF6: a potential therapeutic target in EGFR- and TLR-driven tumorigenesis. Cell Death Dis. 2025 Dec 19; 16(1):894.

View in: PubMed
Shin JH, Kim JY, Kim MJ, Kang Y, Lee HJ, Choi B, Lee JS, Kwon D, Kim SH, Sung Y, Kim DH, Shim JH, Chun E, Lee KY. PYCR1 drives lung cancer progression through functional interactions with EGFR and TLR signaling pathways. Exp Mol Med. 2025 Nov; 57(11):2559-2573.

View in: PubMed
Fuster-Matanzo A, Picó-Peris A, Bellvís-Bataller F, Jimenez-Pastor A, Weiss GJ, Martí-Bonmatí L, Lázaro Sánchez A, Bazaga D, Banna GL, Addeo A, Camps C, Seijo LM, Alberich-Bayarri Á. Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods. Eur Radiol. 2026 Mar; 36(3):2157-2185.

View in: PubMed
Raquel-Cunha A, Pinheiro J, Marques RF, Fontão P, Cardoso-Carneiro D, Mendes A, Gomes INF, Laus AC, da Silva-Oliveira RJ, Reis RM, Martinho O. RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR-targeted therapies. Mol Oncol. 2025 11; 19(11):3205-3222.

View in: PubMed
Yerramilli VS, Lin G, Reisinger JL, Hemmerlin RM, Lindberg SK, Plante K, Ross AH, Gericke A, Scarlata S. The scaffolding protein IQGAP1 enhances EGFR signaling by promoting oligomerization and preventing degradation. J Biol Chem. 2024 11; 300(11):107844.

View in: PubMed
Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S. EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon ?-accelerated murine lupus. Int Immunopharmacol. 2024 Oct 25; 140:112692.

View in: PubMed

People

Explore

Similar Concepts

Top Journals